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BACKGROUND: Clinical outcome of patients with high-risk melanoma cannot be reliably predicted on the basis of classical
histopathological examination. Our study aimed to determine in melanoma metastases a gene expression profile associated with
patient survival, and to identify and validate marker(s) of poor clinical outcome.
METHODS: Skin and lymph node metastases from melanoma patients (training population) were used to identify candidate prognostic
marker(s) based on DNA microarray analysis. Additional skin metastases (validation population) were used to assess the prognostic
value of the first ranked gene by real-time PCR.
RESULTS: We performed microarray analysis in the training population and generated a list of 278 probe sets associated with a shorter
survival. We used the first ranked gene, tyrosinase-related protein 1 (TYRP1), further measured its expression in the validation
population by real-time PCR and found it to be significantly correlated with distant metastasis-free survival (DMFS), overall survival
(OS) and Breslow thickness. We also found that it was fairly well conserved in the course of the disease regardless of the delay to
metastasis occurrence. Finally, although Tyrp1 protein (immunohistochemistry (IHC)) was only detected in about half of the samples,
we showed that its expression also correlated with Breslow thickness.
CONCLUSION: Our data indicate that TYRP1 mRNA expression level, at least in skin metastases, is a prognostic marker for melanoma,
and is particularly useful when prognostic pathology parameters at the primary lesion are lacking. Its conserved expression further
supports its use as a target for therapy.
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The prognosis of melanoma is based on the histopathological
criteria described in the American Joint Committee on Cancer
(AJCC) melanoma staging system. These include the Breslow
index, mitotic rate, ulceration status and extent of lymph node
involvement (Balch et al, 2009). Despite this staging system, the
clinical behaviour of melanoma is often unpredictable (Nagore
et al, 2005), because melanoma is a group of diseases with various
biological subtypes (Lomas et al, 2008). In addition, patients with
melanoma metastatic to the skin show variable survival: some may
survive for a long time, whereas some die of disseminated disease
within 1 year of removal of skin metastases (Hofmann-Wellenhof
et al, 1996).
Studies based on melanoma gene expression profiling have been
performed in order to improve the prognosis of the disease and to
predict its response to treatment (Hoek, 2007). First, a comparison
of gene expression profiles of normal skin, nevi and primary and
metastatic melanomas has identified 2602 signature genes that
could be used to distinguish two metastatic patterns, which are
already emergent in large primaries (Haqq et al, 2005). Second,
cDNA expression microarray in primary melanoma has revealed a
signature of 254 genes characterising patients at risk of developing
distant metastases (Winnepenninckx et al, 2006). Third, high-
throughput gene microarray in metastatic melanoma has deter-
mined a set of 80 probes (70 genes) associated with survival
(Mandruzzato et al, 2006). Finally, molecular profiling of lymph
node metastases of stage III melanoma patients has disclosed 21
genes whose expression levels correlated with clinical outcome
(John et al, 2008). Thus, several new marker genes have shown
promise, and large-scale studies are now warranted to clinically
validate them for the development of new prognostic tools,
diagnostic approaches and biological-targeted therapies (Larson
et al, 2009).
Such gene discovery platforms may help to identify new
molecular markers in melanoma metastases, enabling one to
refine the prognosis at the time of tumour progression, especially
in thin melanomas. They may also help to establish a prognosis in
patients with unknown melanoma primaries (2–6% of all
melanoma cases) (Schlagenhauff et al, 1997). The identification
of such markers in high-risk melanoma patients would be
Received 4 May 2011; revised 3 October 2011; accepted 5 October
2011; published online 1 November 2011
*Correspondence: Dr G Ghanem; E-mail: gghanem@ulb.ac.be
7Current address: Department of Pathology, McGill University/Jewish
General Hospital, Montreal, Quebec, Canada.
British Journal of Cancer (2011) 105, 1726 – 1732
















important for the design and the interpretation of clinical trials,
and could be of great benefit as one might also foresee the
development of useful and effective adjuvant therapies.
This work describes a gene profiling study in skin and lymph
nodes, which are the most frequent melanoma metastases, that
shows an inverse correlation between tyrosinase-related protein 1
(TYRP1) expression level and patient overall survival. A validation
study using quantitative PCR only in skin metastases further
supports TYRP1 as a new marker of poor clinical outcome.
MATERIALS AND METHODS
Patients and tissue collection
Skin and lymph node metastases were collected from patients with
stage III melanoma undergoing surgery at Institut Jules Bordet.
Samples (mean size 10mm, no necrosis) were collected randomly
with no inclusion or exclusion criteria. Half of each biopsy was
fixed in formalin, embedded in paraffin, sectioned according to
routine clinical procedures and was used for immunohistochem-
istry. The other half was snap-frozen in liquid nitrogen and stored
at 80 1C, and was dedicated to microarray analysis and real-time
PCR. Microdissection has been carried out by one surgeon (FS) on
each sample before any snap freezing. This study was approved by
the ethic committee of Institut Jules Bordet and performed in
accordance with the REMARK guidelines (Alonzo, 2005; McShane
et al, 2005). The clinical characteristics of the patients are outlined
in Table 1.
RNA extraction
Frozen samples were homogenised using the FastPrep-24 homo-
geniser system with lysing matrix D (MP Biomedicals, Illkirch
Cedex, France) in RLT buffer supplemented with b-mercapto-
ethanol (RNeasy Mini Kit, Qiagen, Venlo, The Netherlands) at 4 1C.
Centrifugation with RNeasy spin column separated melanin from
the total RNA. After washing steps, RNA was collected in RNase-
free water and RNA concentrations were evaluated using
a NanoDropTM 1000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). RNA quality of each sample was assessed
based on the RNA profile generated by the bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
Microarray analysis
Gene expression profiling was performed with the training
population using the Affymetrix technology (Affymetrix, Inc.,
Santa Clara, CA, USA). RNA was hybridised on Human Genome
U133 Plus 2.0 Array. The scanning of the chips was done according
to standard Affymetrix protocols. Image analysis and probe
quantification were performed with the Affymetrix software that
produced raw probe intensity data in the Affymetrix CEL files.
Before statistical analysis, data were loaded and normalised (RMA
program) using the software package BRB Array Tools (http://
linus.nci.nih.gov/BRB-ArrayTools.html). A class comparison was
performed between groups of arrays based on patient survival
(group 1 (N¼ 10): overall survival (OS) o30 months; group 2
(N¼ 22): OS X30 months) sorting probe sets passing filtering
criteria (significant at 0.05 level of the univariate two-sample t-test
and fold change strictly 42.5). To assess a possible bias due to a
difference in tumour burden, the expression of the specific
melanocyte marker S100B was compared between both groups.
Real-time PCR
The TYRP1 mRNA expression was quantified by real-time PCR.
cDNA was synthesised using a standard reverse transcription
method (qScript cDNA SuperMix, Quanta Biosciences, Gaithers-
burg, MD, USA). Real-time PCR reactions were performed using
the SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA, USA) and sequence-specific primer sets for TYRP1 (forward¼
50-CCGAAACACAGTGGAAGGTT-30, reverse¼ 50-TCTGTGAAGG
TGTGCAGGA-30), for S100B (forward¼ 50-ATTCTGGAAGGGAGG
GAGAC-30, reverse¼ 50-CGTGGCAGGCAGTAGTAACC-30) and for
b-actin (forward¼ 50-CTGGCACCCAGCACAATG-30, reverse¼
50-CCGATCCACACGGAGTACTTG-30) (Sigma-Genosys, Pampis-
ford Cambs, UK). The amplification was performed on an ABI
PRISM 7900HT Sequence Detection System (Applied Biosystems)
using 40 cycles of a two-step PCR (15 s at 95 1C and 60 s at 60 1C)
after an initial activation step (95 1C for 10min). Melting curves
from 60 1C to 99 1C were assessed to evaluate PCR specificity. Serial
dilutions of purified amplicons were utilised to generate standard
melting curves. The mRNA expressions of TYRP1 and S100B were
normalised to b-actin (loading control). The S100B is one of the
most reliable biomarkers for melanoma and it is commonly used
as a marker for tumour load.
Immunohistochemistry
For Tyrp1 immunostaining, dewaxed tissue sections were rehy-
drated in distilled water, incubated for 1 h in distilled water at
85 1C, and exposed for 5min to 0.5% H2O2. Thereafter, the
sections were rinsed in phosphate-buffered saline (PBS), incubated
for 15min in PBS containing 0.5% casein, and then exposed for 1 h
to a primary antibody raised against the carboxyterminal end of
Tyrp1 protein (mouse monoclonal anti-Tyrp1, dilution 1 : 50, clone
G3E6; Abcam, Cambridge, UK), and for additional 30min to a
secondary antibody raised against mouse immunoglobulins and
conjugated with horseradish peroxidase (HRP-conjugated goat
polyclonal anti-mouse IgG, dilution 1 : 50; Abcam). Bound
peroxidase activity was visualised by incubation in the presence
of H2O2 and 3-amino-9-ethylcarbazole (AEC substrate) (Vector
Laboratories, Burlingame, CA, USA). The sections were counter-
stained with hemalun, mounted using an aqueous-based medium
(Vectamount AQ, Vector), and analysed as described in Figure 3.
Statistical analysis
For statistical analyses of microarray and real-time PCR data,
intensity values were log-transformed to a base-2 scale. False
discovery rate (FDR) was determined using the software BRB
Array Tools. Statistical correlation between two variables was
assessed using Spearman’s rho test. Statistical significance between
two independent groups was examined using the Mann–Whitney
test. Variations of TYRP1 expression during time in different





Number of samples 32 89
Type of metastasis
Skin 13 89




Median age (range), yearsa 49 (26–88) 58 (20–88)
Median Breslow (range), mmb 2.0 (0.9–9.1) 3.2 (0.3–15)
Median DMFS (range), months 14 (0–105) 9 (0–293)
Median OS (range), months 49 (8–186) 45 (6–334)
Abbreviations: DMFS¼ distant metastasis-free survival; OS¼ overall survival. aAge at
the diagnosis of primary melanoma. bBreslow is the thickness of primary tumours as
determined by histopathological examination.
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patients were tested by Kruskal–Wallis test. Distant meta-
stasis-free survival (DMFS) and OS were estimated using the
Kaplan–Meier method. Univariate analyses of relapse/death were
performed using Cox’s proportional hazards method. Significance
of the positive predictive value was determined by Fisher’s exact
test. The P-values of o0.05 were considered as statistically
significant. All statistical analyses were performed using SPSS
15.0 Inc. (Chicago, IL, USA).
RESULTS
Characteristics of melanoma patients
The characteristics of the training and the validation populations
are in Table 1. A large majority of patients (95%) had primary
melanoma with a Breslow thickness 41mm and thus an
unfavourable prognosis (however, 5 patients in the validation
population had tumours with o1mm thickness). In the training
population, all patients deceased, whereas in the validation
population some patients were lost for follow-up (6 out of 89) or
were still alive (10 out of 89) over a period of up to 25 years.
Identification of genes related to survival in the training
population
The training population was subjected to microarray analysis as
described in the Materials and Methods. A class comparison
between two groups of samples from patients with different
survival sorted 278 probe sets passing filtering criteria (Supple-
mentary Table 1). The first ranked gene was TYRP1 (fold
change¼ 33.9, P¼ 0.00004), which actually codes for an enzyme
involved in melanogenesis, a unique feature restricted to
melanocytes. Interestingly, among the other highly ranked
upregulated probe sets, five genes were also associated with the
pigmentation (SILV, DCT, OCA2, TYR and MITF; Table 2),
suggesting that many melanogenesis markers could be associated
with shorter survival. A possible bias due to a difference in tumour
burden was checked using S100B, and data showed that the latter
marker did not differ significantly between the two groups
(Table 2, Control). The TYRP1 was then chosen to be further
evaluated as a new potential marker of poorer prognosis.
Comparison of probe set signature and TYRP1 mRNA in
the training population
In order to determine if TYRP1 mRNA expression genuinely
reflected the 278 probe set signature, scores of the signature
and TYRP1 were calculated as follows: the score of probe
set signature was the mean expression levels (log-transformed
values) of upregulated genes minus the mean expression levels
(log-transformed values) of downregulated genes, and the score of
TYRP1 was the log-transformed value. First, there were significant
correlations between the score of the probe set signature and the
score of TYRP1 (r¼ 0.719, Po0.001, Spearman’s rho). Second,
TYRP1 mRNA expression was significantly higher (Po0.001,
Mann–Whitney test) in the subpopulation of patients with poor
prognosis (group 1). Hence, TYRP1 mRNA expression was actually
as informative as the probe set signature with respect to patient
survival.
Validation of TYRP1 microarray data by real-time PCR
Training population Microarray data were validated by real-time
PCR measurement of TYRP1 mRNA expression in the skin
metastases (N¼ 13) of the training population. We validated the
microarray data on skin metastases only in order to match with the
validation population. Results showed a significant correlation
between microarray and PCR data (r¼ 0.780, P¼ 0.002, Spear-
man’s rho). Accordingly, TYRP1 mRNA expression (real-time
PCR) was significantly higher (P¼ 0.001, Mann–Whitney test) in
group 1 (OS o30 months) when compared with group 2 (OS X30
months).
Validation population The expression of TYRP1 mRNA was
evaluated by real-time PCR in an independent cohort of skin
metastases (N¼ 89, Table 1, validation population). The popula-
tion was divided into quartiles on the basis of TYRP1 levels and
subgroups were subjected to Kaplan–Meier analysis. The quartile
corresponding to the lowest TYRP1 levels presented a better
survival when compared with the three other quartiles (higher
TYRP1 levels), for which the Kaplan–Meier curves were not
significantly different (DMFS P¼ 0.221, OS P¼ 0.112, Cox regres-
sion). Therefore, a cutoff point at the first quartile was set in order
to divide the population in two groups of ‘low’ and ‘high’ TYRP1
mRNA levels. Hence, in the validation population, high TYRP1
mRNA expression was significantly associated with a shorter
DMFS and a shorter OS (Figure 1). A possible difference in tumour
burden between the two groups was checked by real-time PCR of
S100B and the analysis did not reveal significant difference
(P¼ 0.91; Mann–Whitney). Accordingly, we found a very good
correlation between TYRP1/b-actin and TYRP1/S100B ratios
(r¼ 0.770, Po0.001, Spearman’s rho), indicating that S100B and
b-actin changes are closely related, and further supporting no
significant difference in tumour load.
Serial measurements of TYRP1 expression in recurrent
skin metastases of the same patient
As the data suggest that TYRP1 mRNA expression in skin
metastases has prognostic value regardless of the time of their












1 0.00004 0.15 687.4 20.3 33.9 205694_at TYRP1 Tyrosinase-related protein 1
2 0.00040 0.19 3077.2 186.7 16.5 209848_s_at SILV Silver homolog (mouse)
4 0.00103 0.20 1291.6 97.0 13.3 205338_s_at DCT Dopachrome tautomerase
(tyrosine-related protein 2)
13 0.00174 0.21 145.3 18.0 8.1 206498_at OCA2 Oculocutaneous albinism II
15 0.02823 0.33 3170.1 496.5 6.4 206630_at TYR Tyrosinase (oculo-cutaneous albinism IA)
99 0.02147 0.32 1054.3 375.4 2.8 207233_s_at MITF Microphthalmia-associated transcription factor
Controlc 0.649 — 929.0 1145.2 0.8 209686_at S100B S100 calcium binding protein B
Abbreviations: Geom¼ geometric; FDR¼ false discovery rate; OS¼ overall survival. aPosition in the complete list (278 probe sets). bTwo-sample t-test. cAssessed as control for
difference in tumour load.
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development (median: 30 months, range: 1–332), it was measured
in five consecutive metastases resected from each of five
patients (Figure 2). The mRNA levels of TYRP1 remained within
a narrow range with a coefficient of variation of o16% for each
patient.
Evaluation of Tyrp1 protein expression in skin metastases
The expression of the protein (Tyrp1/gp75) was examined by
immunohistochemistry (IHC) in a panel of paraffin-embedded
biopsies from the skin metastases of the validation population
(N¼ 52; Figure 3). The Tyrp1 protein immunoreactivity was
apparent only in 48% of cases positive for TYRP1 mRNA
expression. However, in samples with positive staining, there was
a significant correlation between staining scores and mRNA levels
(real-time PCR) (r¼ 0.488, P¼ 0.034, Spearman’s rho).
Correlation between TYRP1 mRNA or Tyrp1 protein and
prognostic parameters at primary
The expressions of TYRP1 mRNA and Tyrp1 protein in skin
metastases were correlated with the AJCC prognostic parameters at
diagnosis (Table 3). Both TYRP1 mRNA and Tyrp1 protein
expressions significantly correlated with Breslow thickness. Non-
significant trends were recorded between Tyrp1 protein and the
ulceration status or the number of positive lymph nodes. Thus,
TYRP1 mRNA and Tyrp1 protein expressions in cutaneous
melanoma metastases remain associated with prognostic features
of the corresponding primary lesions, regardless of the interval
between the diagnosis of the primary and the occurrence of the
cutaneous metastases.
DISCUSSION
First, 278 probe sets associated with a short survival of patients
with melanoma metastases have been identified by microarray
analysis in skin and lymph node metastases. The TYRP1
expression ranked first and, alone, was predictive for DMFS and
OS as validated in skin metastases, with the skin being the first site
of recurrence (56% of all patients) (Savoia et al, 2009). The TYRP1
also significantly correlated with Breslow thickness, which is the
most accurate prognostic parameter of the corresponding primary
lesion, and thus brings information that is quite different, although
complementary, from the ‘mitotic index’ that is calculated at the
time of metastasis itself (Bogunovic et al, 2009).
We ruled out any possible bias due to variation in tumour
burden between the compared groups in both the training and
validation populations by analysing the specific melanocyte
marker S100B; the latter showed no difference in expression.
Moreover, as TYRP1 gene is related to pigmentation and is
exclusively expressed in melanocytes and melanoma cells, the
documented changes in its expression is restricted to tumour
tissues.
Corroborating our results, a previous study reported that the
repression of TYRP1 is concomitant to the induction of an isoform
of the microtubule-associated protein 2 (MAP-2), a marker of
immature neurons (Fang et al, 2001), and that patients with
MAP2-positive (hence, low TYRP1) primary melanomas have a
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Figure 1 The TYRP1 mRNA expression and survival of 89 patients with melanoma skin metastases. The distant metastasis-free survival and the overall
survival curves (Kaplan–Meier analysis) were determined for patients of the validation population. Patients were distributed according to the TYRP1 mRNA
levels (real-time PCR determination) as defined in the ‘Results’. Cox regressions were calculated to determine P-values, hazard ratios (HRs) and 95%
confidence intervals (CIs). The symbol ‘þ ’ indicates the patients who were alive at the time of analysis. The mRNA expression of TYRP1 had a positive







































Figure 2 Variation of TYRP1 mRNA expression levels over time in
recurrent skin metastases within the same patient. The levels of expression
of TYRP1 mRNA were evaluated in quadruplicate by real-time PCR in five
different melanoma skin metastases obtained over years from each of five
patients. The TYRP1 mRNA levels (median) are plotted against time from
diagnosis of primary. Dashed line indicates the median value of TYRP1
mRNA expression for each patient. For each patient, TYRP1 mRNA levels
were compared using Kruskal–Wallis test (%significant). A weak significant
difference was calculated in patient 1 (P¼ 0.03).
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Importantly, TYRP1 sorted together with five other melanogen-
esis-related genes (SILV, DCT, OCA2, TYR and MITF), which were
also contained in the probe set signature, point to an active
pigmentation process. In this context, a previous study using
cDNA microarray analysis showed that high expression of DCT/
TYRP2 in metastatic melanoma was associated with a shorter
patient survival (Mandruzzato et al, 2006). The question is why
would a melanocyte differentiation marker, such as TYRP1, be
associated with survival? The hallmark of differentiated melano-
cytes is an active pigmentation process that may increase with
tumour burden. In addition, as melanoma cells are coupling
proliferation and differentiation through MITF (Wellbrock et al,
2008), the transcription factor that control the synthesis of TYR,
TYRP1 and DCT genes (Murisier and Beermann, 2006), we may
reasonably assume that high level of expression of genes involved
in melanogenesis results from a net balance of the MITF activity.
Besides the possible role of human Tyrp1 as a melanogenic
enzyme (Hearing et al, 1992), several observations provide
evidence supporting its putative implication in cell survival. First,
Tyrp1 mutation or decrease in expression interferes with
melanosome maturation in mouse melanocytes and, most inter-
estingly, attenuates cell proliferation, without evidence of necrosis
or apoptosis (Sarangarajan et al, 2000). Second, both Tyrp1 and
Dct/Tyrp2 protect the melanocyte against the cytotoxicity of toxic
melanin intermediates produced by tyrosinase, without affecting
tyrosinase expression or its activity (Rad et al, 2004).
Tyrp1 score=0 Score=250m
Score=5
Score=7 + melaninScore=0 + melanin
Score=7
Figure 3 Representative micrographs of Tyrp1 protein expression in paraffin-embedded specimens of melanoma skin metastasis. The expression of
Tyrp1 protein was evaluated by immunohistochemistry in 52 amelanotic or pigmented samples. A score from 0 to 8 was calculated by adding a score
reflecting the proportion of positively stained cells (none¼ 0; o1/100¼ 1; 1/100 to 1/10¼ 2; 1/10 to 1/3¼ 3; 1/3 to 2/3¼ 4; and 42/3¼ 5) to a score
reflecting the staining intensity (none¼ 0; weak¼ 1; intermediate¼ 2; and strong¼ 3). Cytoplasmic red staining was considered as positive. Brown granules
represent melanin pigment.
Table 3 Association of TYRP1/Tyrp1 mRNA/protein expression with
pathological parameters of primaries












Abbreviation: TYRP1¼ tyrosinase-related protein 1. aCorrelation test (Spearman’s rho).
bNumber of positive lymph nodes at primary. cNonparametric test (Mann–
Whitney). Bold numbers indicate significant P-values.
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The discrepancies between TYRP1 mRNA levels (frozen tissue
samples) and Tyrp1/gp75 protein expression (corresponding
paraffin embedded samples) that we found in skin metastases of
about half of the patients, including some with high TYRP1 mRNA
expression but no protein if any, may suggest possible post-
transcriptional and/or post-translational events altering the
protein recognition by the antibody despite the best choice of
the G3E6 antibody that recognises the unglycosylated C-terminus
of the protein. Our finding of this discrepancy as well as the use of
various anti-Tyrp1 antibodies in previous studies could explain the
previously reported lack of association between Tyrp1 protein
expression and disease-free or OS (Bolander et al, 2008), and the
absence of Tyrp1 protein in the vertical/invasive growth phase of
primary lesion (Fang et al, 2001). Furthermore, no or low
expression of Tyrp1 protein might be explained by (1) the absence
of a putative Tyrp1 chaperone, such as calnexin, which is required
to stabilise the protein (Jimbow et al, 1997), (2) a defect in PI3K-
dependent Tyrp1 maturation and trafficking to melanosomes
(Chen et al, 2001), and/or (3) a loss of Rab proteins, such as Rab38/
32, which are involved in the stability of melanogenic enzymes
(Wasmeier et al, 2006).
On the other hand, as the activation of melanogenesis enzymes
may lead to visible pigmentation, the latter was checked in the same
IHC slides, but no correlation was found with Tyrp1 protein
expression (example in Figure 3). This finding is consistent with
previous studies showing that Tyrp1 can be regulated independently
of tyrosinase and pigmentation in mature melanocytes (Vijayasaradhi
et al, 1995) and that tyrosinase mRNA or protein expression does not
always correlate with pigmentation (Watabe et al, 2004).
Finally, our findings of an association between high TYRP1/
Tyrp1 levels and shorter patient survival, together with a
conserved TYRP1 expression throughout the course of the disease,
are in line with previous clinical studies that identified circulating
anti-Tyrp1 autoantibodies in melanoma patients (Mattes et al,
1983) and that demonstrated melanoma rejection and higher
survival in mice treated with a mouse monoclonal antibody against
Tyrp1 (Takechi et al, 1996), and support the recent clinical
development of a new human anti-Tyrp1 monoclonal antibody for
melanoma immunotherapy (Patel et al, 2007) (http://clinicaltrials.-
gov/ct2/show/NCT01137006).
In conclusion, we found that TYRP1 gene expression level in
melanoma skin metastases correlates with both DMFS and OS and
with Breslow thickness. Thus, TYRP1 could emerge as a valuable
prognostic marker, especially in melanoma patients where
important prognostic factors at diagnosis cannot be evaluated
(namely unknown or ulcerated primaries) and in metastases of
thin melanomas. Our observation of a fairly conserved TYRP1
expression during disease progression further supports its use as a
target for antimelanoma therapy.
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